Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar
Yuflyma 100mg/ml Version Of Adalimumab Ready For Launch In Europe
Celltrion has received a pan-European marketing authorization for its Yuflyma high-concentration adalimumab biosimilar, making it the first firm worldwide to register a 100mg/ml rival to the blockbuster Humira brand.
